Trevena (NASDAQ: TRVN): A Biotech Low Float Runner

Trevena (NASDAQ: TRVN) announced that its partner, Jiangsu Nhwa, has received approval from China's National Medical Products Administration (NMPA) for its opioid pain medication, Olinvyk.

Related Keywords

China ,Jiangsu Nhwa ,Carrie Bourdow ,Healthcare Fund ,Exchange Commission ,China National Medical Products Administration ,National Medical Products Administration ,R Bridge Healthcare Fund ,R Bridge Financing ,Inside Scoop ,Right Now ,Stock Halt Alerts ,Dell Thomas Investing ,Featured ,Trvn ,